<DOC>
	<DOC>NCT01982175</DOC>
	<brief_summary>This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.</brief_summary>
	<brief_title>Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>An established diagnosis of Bcell chronic lymphocytic leukemia(BCLL) Meet criteria of relapsed or refractory CLL Presence of one or more measurable lesions ECOG Score 01 Life expectancy &gt; 3 months Female patients with childbearing potential must have a negative serum pregnancy test, male and female patients must agree to use an effective contraceptive method while on study treatment, and for a minimum 1 year following study therapy. Less than 2 weeks from prior anticancer therapy. Allergic to the antibody or any component of the investigational product. Other severe, concurrent diseases, including mental disorders, serious cardiac functional capacity (Class III or IV), uncontrolled diabetes. Use of investigational agents rather than Alemtuzumab. Active systematic infection or major organ malfunction requiring treatment. Serum total bilirubin greater than or equal to 1.5 times upper limits of normal; or Serum alanine aminotransferase (ALT) and/or serum aspartate aminotransferase (AST) greater than or equal to 2.5 times upper limits of normal ( no liver metastases); or ALT and/or AST greater than or equal to 5 times upper limits of normal (liver metastases). Blood urea nitrogen(BUN) greater than or equal to 1.5 times upper limits of normal or Serum creatinine greater than or equal to 1.5 times upper limits of normal. White blood cell(WBC) count&lt; 3.5×109/L or Absolute neutrophil count(ANC)&lt;1.5×109/L or platelet count&lt;75×109/L or Hemoglobin&lt;80g/L. Human immunodeficiency virus (HIV) positive. Active hepatitis or a history of prior viral hepatitis B or C, or positive hepatitis B serologies without prior immunization. Pregnant or nursing women. Known central nervous system(CNS) metastases with BCLL. Active secondary malignancy. cytomegalovirus(CMV) positive or immunodeficiency disease or after stem cell transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>CD52</keyword>
</DOC>